CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet?

Key Takeaways Theravance Biopharma is favored over CorMedix for its balanced risk-reward profile in 2026.TBPH benefits from Yupelri profit-sharing and a $225M Trelegy royalty sale, boosting cash runway.CorMedix expects to face slower 2026 DefenCath growth and pricing pressure amid rising competitive risks.CorMedix (CRMD) and Theravance Biopharma (TBPH) occupy a similar niche in the market as small-cap biopharmaceutical companies working to turn promising science into sustainable revenues. Both companies, ha ...